Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

NCT03628612 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy
Multiple Myeloma
DLBCL
ALL, Adult and Pediatric
T Cell Lymphoma

Interventions

BIOLOGICAL: AUTO CAR T cell therapy

Sponsor

Autolus Limited